Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IOVAthis companyIovance Biotherapeutics, Inc.	$8.17	-2.5×	1.4×	3.7×	-2.45×	-53.5%	34.3%	-151.1%	-148.4%	-56.0%	-50.9%	-34.5%	0.07×	0.33×	0×	3.2×	0.0%	4	9.15	1	C-
ALXOALX Oncology Holdings Inc.	$1.29	-0.59×	2.33×	0×	-0.5×	-89.2%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-3.23	2	C
FATEFate Therapeutics, Inc.	$1.94	-0.85×	0.56×	17.56×	-1.16×	-122.3%	-94.1%	-2222.4%	-2051.1%	-65.8%	-51.4%	-96.0%	0.38×	-0.25×	0×	5.79×	0.0%	2	-9.43	1	C-
IBRXImmunityBio, Inc.	$7.11	-5.21×	-3.65×	16.08×	-11.68×	-390.6%	99.3%	-226.0%	-310.2%	70.3%	-56.9%	-17.0%	-1.76×	-3.53×	-2.28×	5.1×	0.0%	4	-1.24	2	C
IMNMImmunome, Inc.	$19.36	-8.84×	2.96×	270.32×	-5.86×	-62.2%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	23.32	2	C+
LEGNLegend Biotech Corporation	$24.29	-13.59×	4×	3.89×	-15.15×	-8736.1%	60.3%	-13.3%	-28.8%	-29.6%	-9.6%	-4.2%	0.41×	2.1×	-6.38×	1.96×	0.0%	3	4.77	1	C-
Peer median	—	-5.21×	2.33×	16.08×	-5.86×	-122.3%	57.4%	-226.0%	-310.2%	-33.5%	-51.4%	-17.0%	0.2×	0.11×	-2.28×	5.1×	0.0%	2	-1.24	2	—